We adopted a comprehensive multi-omics approach to identify ALKBH1 as an potential diagnostic biomarker for STAD, demonstrating its association with advanced clinical stages and reduced overall survival rates. This evidence concerns the gene ALKBH1 and gastric adenocarcinoma.